Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
|Articles|February 16, 2018
ABEC Expands Single-Use Manufacturing Capability
Author(s)BioPharm International Editors
The company has expanded its single-use manufacturing capabilities at its facility in Fermoy, Ireland.
Advertisement
On Feb. 13, 2018, ABEC, a provider of integrated solutions and services for biopharmaceutical manufacturing, announced the completion of its second International Standards Organization-compliant cleanroom for single-use disposable container (DC) manufacturing at its Fermoy, Ireland, facility.
The new Fermoy cleanroom will strengthen ABEC’s custom single run single-use product offerings and will be operational in April 2018, according to the company. The
“A flexible and reliable supply of high quality DC’s is critical to our customers’ single-use manufacturing operations,” said Scott Pickering, ABEC President and CEO, in a company press release. “ABEC’s new state-of-the art cleanroom in Fermoy greatly enhances our DC supply capability and further reduces our customers’ single-use supply chain risk.”
Source:
Advertisement
Related to this article
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
Advertisement
Advertisement
Trending on BioPharm International
1
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
2
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
3
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
4
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
5